

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	60	-	60	=	0	\$ 18	\$0.00
INDEPENDENT	2	-	3	=	0	\$ 84	\$0.00
_____ FIRST PRESENTATION OF A MULTIPLE CLAIM						\$270	\$0.00
						TOTAL	\$0.00

Docket No. 0147-0221P

- ☐ Petition for () month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ A check in the amount of \$0.00 is enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP


By *my N. all* 36,623
Leonard R. Svensson, #30,330

LRS/BCF
0147-0221P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment

(Rev. 01/22/01)



BOX SEQUENCE
PATENT
0147-0221P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: SPIESS, Joachim et al. Conf.: 5077
Appl. No.: 09/744,441 Group: UNASSIGNED
Filed: May 11, 2001 Examiner: UNASSIGNED
For: ANTAGONISTS SPECIFIC FOR THE CORTICOTROPIN-
RELEASING FACTOR RECEPTOR TYPE 2 (CRFR2)

AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

November 6, 2002

Sir:

In response to the Notification of Defective Response mailed October 7, 2002, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

In the Specification:

Please replace the paragraph on page 4 line 27 with the following amended paragraph:

-- In a more preferred embodiment the antagonist of the present invention comprises the amino acid sequence Xaa₁-Xaa₂-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH₂ (SEQ ID NO: 1), wherein Xaa₁ is a neutral amino acid, and Xaa₂ is a changed amino acid. --